Actively Recruiting
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Led by Immune Oncology Research Institute · Updated on 2026-06-05
200
Participants Needed
22
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare blood cancer with no agreed-upon best treatment. Researchers are working internationally to gather detailed information on how BPDCN presents, how it is diagnosed, the treatments patients receive, and their outcomes. The study aims to build a large database to better understand the disease and to develop treatment recommendations based on collected data. This study is an international registry collecting information from multiple centers about patients diagnosed with BPDCN. It includes both retrospective and prospective data from patients worldwide. The data collected covers patient details, disease characteristics, treatment information, outcomes, causes of death, and the conclusion of data collection. Consent will be obtained from prospective patients, and quality control is managed by the Immune Oncology Research Institute. Participants will provide information through questionnaires completed by their treatment centers. Researchers will analyze overall survival, complete remission rates, duration of first remission, and event-free survival over five years. This observational study does not involve treatment but gathers and monitors detailed clinical data to improve understanding and guide future therapies for BPDCN.
CONDITIONS
Brief Title
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of BPDCN
- Signed informed consent form for prospective patients
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants who have been diagnosed with BPDCN are observed to collect data on patient characteristics, treatment details, outcomes, and survival over time.
Trial Site Locations
Total: 22 locations
1
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, United States, 33136
Actively Recruiting
2
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
3
Seattle Children's Cancer and Blood Disorders Center
Seattle, Washington, United States, 98145
Actively Recruiting
4
Hematology Center named after prof. R. Yeolyan
Yerevan, Armenia, 0014
Actively Recruiting
5
University of Calgary
Calgary, Alberta, Canada, T2N 1N4
Actively Recruiting
6
Children's Hospital of Eastern Ontario, University of Ottawa
Ottawa, Ontario, Canada, K1H 8L1
Actively Recruiting
7
Cyprus Society of Haematology
Nicosia, Cyprus, 2019
Actively Recruiting
8
Oncology Center, Mansoura University Faculty of Medicine
Al Mansurah, Egypt, 7650030
Actively Recruiting
9
M. Iashvili Children's Central Hospital
Tbilisi, Georgia, 0159
Actively Recruiting
10
Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences
New Delhi, India, 110029
Actively Recruiting
11
Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad
Baghdad, Iraq, 61023
Actively Recruiting
12
University of Perugia - Azienda Ospedaliera Perugia
Perugia, Italy, 06129
Actively Recruiting
13
Department of Biomedicine and Prevention, University of Rome Tor Vergata
Roma, Italy, 00133
Actively Recruiting
14
King Hussein Cancer Center (KHCC)
Amman, Jordan, 11941
Actively Recruiting
15
Department of hematology, Kuwait Cancer Control Center
Kuwait City, Kuwait, 42262
Actively Recruiting
16
Fundeni Clinical Institute, Department of Acute Leukemia
Bucharest, Romania, 022328
Actively Recruiting
17
China Medical University Children's Hospital
Taichung, Taiwan, 40447
Actively Recruiting
18
Turkish Pediatric Cancer Registry
Ankara, Turkey (Türkiye), 06690
Actively Recruiting
19
Istanbul University, Oncology Institute
Istanbul, Turkey (Türkiye), 34093
Actively Recruiting
20
University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit
Istanbul, Turkey (Türkiye), 34766
Actively Recruiting
21
Broomfield Hospital, Haematology Mid and South Essex University Hospitals Group
Chelmsford, Essex, United Kingdom, CM1 7ET
Actively Recruiting
22
United Lincolnshire Teaching Hospital NHS Trust
Lincoln, Lincolnshire, United Kingdom, LN2 5QY
Actively Recruiting
Research Team
A
Astghik Voskanyan, MD
D
Davit Melkonyan
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here